Studies have shown that HuR is highly expressed in breast cancer, colorectal cancer, gastric cancer, and prostate cancer, and is closely related to clinicopathological features, lymph node metastasis, low survival rate, and poor prognosis of cancer patients [5–9]. This evidence concerns the gene ELAVL1 and cancer.